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An increased risk of second malignancy is well recognized in patients treated for plasma cell neoplasms. However, second
solid tumor is very rare in such patients. We report a case of a 68-year-old woman with plasmacytoma who developed lung
adenocarcinoma.
1. Introduction
The development of effective treatment for hematological
malignancy has resulted in a large number of long-term
survivors. As a result of survival elongation, second malig-
nancy has been increasingly recognized [1, 2]. In patients with
multiple myeloma, elevated risks of acute myeloid leukemia
(AML) and myelodysplastic syndrome (MDS) have been
described for over 4 decades. On the other hand, second solid
malignancy is very rare in such patients [3, 4]. We present a
case of lung adenocarcinoma in a patient with plasmacytoma
and discuss the pathogenesis of the occurrence of lung cancer
(LC) in this patient.
2. Case Report
A 68-year-old woman, who had been a heavy smoker (40
cigarettes/day for 45 years), was admitted to the Mie univer-
sity hospital with lumbago and progressive lower body paral-
ysis inMay 2001. She received an emergent operation because
of the compression of the spinal cord by the decompression
fracture of the 1st lumbar vertebra. A diffuse accumulation of
plasma cells was disclosed by the pathological examination
of the bone tissue taken at that time (Figure 1). Although
serum immunoglobulin (Ig) levels were not increased (IgG
1205mg/dL), serum immunoelectrophoresis showed a mon-
oclonal IgG-𝜆 bow. No increased number of plasma cells
was observed in the bone marrow from the sternum and
the ilium. Bone scintigraphy showed an increased uptake
in the 1st lumbar vertebra and the left humerus. She was
diagnosed with multiple plasmacytoma and received local
radiation therapy (RT) for their lesions (35Gy each). After
a while, new lesions continuously appeared, and all of
those were treated with local RTs: the sternum (40Gy) in
December 2001, the right femur (35Gy) in February 2002, the
right sacroiliac articulation (35Gy) in April 2002, the right
humerus (30Gy) in December 2002, the left breast (50Gy)
in June 2003, the left jaw (40Gy) in April 2004, the right
11th rib (35Gy) in May 2004, the left kidney surrounding
lesion (40Gy) and the anterior bladder lesion (40Gy) in
May 2006, and the mediastinum (40Gy) and the right fibula
(40Gy) in September 2006. Lumpectomy was performed for
the left breast lesion, which was confirmed as plasmacytoma.
Chemotherapy with melphalan (6mg/day) and prednisolone
(40mg/day) for 4 days every 4–6 weeks was also initiated
in November 2006. After 37th courses of this regimen, she
was admitted to our hospital because of dyspnea in January
2011. Chest computer tomography (CT) scan revealed mul-
tiple tumors in the bilateral lungs and a right-sided pleural
effusion (Figure 2). Carcinoembryonic antigen was elevated
(47.0 ng/mL). A chest tube was inserted into her right pleural
cavity and the effusion fluid was drawn out. Cytology of
this fluid revealed adenocarcinoma (Figure 3). Mutations of
epidermal growth factor receptor gene in these cancer cells
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Figure 1: Histological features of the tumor in the 1st lumber vertebra. (A) Dense infiltrates of monomorphic plasma cells were seen
(hematoxylin-eosin stain). (B) Plasma cells were positive for immunoglobulin 𝜆 light chain (immunohistochemical stain).
(a) (b)
Figure 2: Chest CT scan demonstrated multiple tumors in the bilateral lungs and a right-sided pleural effusion.
were not detected. In March 2011, she died of respiratory
failure irrespective of various supportive therapies. Autopsy
was not done.
3. Discussion
The treatment of plasma cell malignancy has progressed
in the past 4 decades. These advances, however, have been
accompanied by a concern for second malignancies. The
development of AML and MDS has been described in
patients with multiple myeloma treated with an alkylat-
ing agent, melphalan, and/or an immunomodulatory drug,
lenalidomide [1, 2]. Our case developed LC following
chemotherapy with melphalan for about 4 years. However,
the incidence and diversity of solid malignancy in myeloma
patients has been reported to be similar to those of normal
persons of the same age [3, 4]. While in patients with
Hodgkin’s lymphoma (HL), Travis et al. [5] reported that
the risk of LC significantly elevated within 1–4 years after
treatment with alkylating agents such as mechlorethamine
and procarbazine. These observations suggest that the alky-
lating agent used for myeloma seems to be unrelated to the
pathogenesis of second solid tumors.
On the other hand, RT may also have a potential role
in the development of therapy-induced malignancies. RT is
themost effective standard treatment of plasmacytoma [6, 7].
In patents with HL, many studies have noted the largest
risk for LC as late effects of successful RT [5, 8–10]. As for
the total dose of RT given to the patient, more than 9Gy
was described to be related to the elevated risk of LC in
HL patients [8, 11]. An excess risk of LC following RT was
suggested to begin 5 years after treatment [5]. Furthermore,
some studies have reported a higher risk of LC after HL in
smokers than in nonsmokers [8, 11]. Even in breast cancer,
postmastectomy RT was also demonstrated to significantly
increase the risk of LC [12–15]. Our patient was treated with
RTs (more than 50Gy) to the left breast and mediastinum
about 5 years ago. Some lung fields were involved by such
radiation exposures. Moreover, she was a heavy smoker for
45 years. Previous studies have identified the joint effects
of cigarette smoking and postmastectomy RT on LC risk.
Therefore, RT coupled with smokingmight be also associated
with the development of LC in our case. Concerning the
morphology of LC after RT, squamous cell carcinoma was
reported to be the most common subtype [14]. However, our
case revealed adenocarcinoma. Kaufman et al. [15] described
that smoking and postmastectomy RT were associated with
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Figure 3: Adenocarcinoma cells in the pleural effusion. (A) Papanicolaou stain. (B) May-Giemsa stain.
all histologic types of LC.Accordingly, no particular tendency
in the LC subtype may be found in patients like our case.
Unlike multiple myeloma, as RT could be used frequently
for plasmacytoma, such a case may have a possibility of
the development of RT-induced malignancy. In this case,
although the coincidental coexistence of double cancers
could not be completely denied, we should pay attention to
the occurrence of LC in patientswith plasmacytoma receiving
chest involvedRTs aswell as patientswithHLor breast cancer,
especially in heavy smokers.
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